key: cord-0953555-svmvd157
authors: Singh, Aditya; Premkumar, Madhumita; Singh, Virendra
title: Liver Injury in COVID-19 – The culprit may not be COVID-19!
date: 2021-03-19
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.03.010
sha: e2b1eba35ab22fd008c65a701abbb424d96058a0
doc_id: 953555
cord_uid: svmvd157

nan

independent predictors of mortality in patients with coronavirus disease of 2019 (COVID- 19) . They developed a prognostic model with a nomogram that can be used to predict the overall survival probability in patients with COVID-19. Importantly, they have reported that chronic hepatitis B virus (HBV) infection is not associated with increased risk of lethal outcomes in patients with COVID-19. Previous studies have revealed that liver abnormalities occur more frequently in patients with severe COVID-19 and this has been consequential in establishing the association between various liver function abnormalities and their effect on mortality in COVID-19 (2) . This is due to the multiplier effect of multiple organ dysfunction, cytokine storm, drug effects and hypoxic liver jury, rather than direct cytopathic effect of the 

Although most patients developed some transaminitis during admission, there were several confounding factors that blur the direct association of liver dysfunction attributable to COVID-19. Cai et al (6) reported use of drugs, systemic inflammation, secondary sepsis, polypharmacy, shock and hypoxia as contributors to liver injury in COVID-19. The presence of hypoxic injury (7) is also a contributor of liver injury and has not been described in the study. It is evident from the description that the hospitalized patients in this cohort were sick, with most requiring high flow oxygen or invasive ventilation which could have contributed independently to the liver injury. Also, the use of various medications during the hospital course should be included in the analysis. The use of hepatotoxic drugs like lopinavir and ritonavir have shown to be associated with liver injury (6) . Alcohol abuse or use of Chinese herbal medication before admission should also be determined and adjusted for in multivariate analysis as that can be a potential contributor to liver injury (8) . The large number of drugs used in clinical trials and variable management of such patients based on evolving evidence also makes comparisons of cohorts difficult. (9) In conclusion, we believe that Ding et al (1) have meticulously analyzed various liver biochemistry abnormalities during COVID-19. However, the retrospective nature of the cohort, limitations of data, lack of external validity to patients with cirrhosis the other confounding factors described merit further investigation and research. With the available evidence, and it would be premature to attribute deranged liver function to COVID-19 infection alone.

The authors received no financial support to produce this manuscript.

J o u r n a l P r e -p r o o f

Association of liver abnormalities with in-hospital mortality in patients with COVID-19

Clinical Characteristics of Coronavirus Disease 2019 in China

Systematic review with meta-analysis: liver manifestations and outcomes in COVID

High rates of 30-day mortality in patients with cirrhosis and COVID-19

High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry

COVID-19: Abnormal liver function tests

Hypoxic Liver Injury

Traditional Chinese Medicine and Herb-induced Liver Injury: Comparison with Drug-induced Liver Injury

Working Group for Liver Derangement during the COVID-19 Pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement

The authors declare no conflicts of interest.

AS: writing and critical revision, MP: writing and critical revision, VS: writing and critical revision.